TCL Archive CALGB Says Results In Adjuvant Setting Too Preliminary; Follow Up Planned In Three Years April 16, 1999
TCL Archive CMF Studies Show Higher Recurrence for Post-Menopausal Patients – Caldwell November 12, 1976
TCL Archive Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials. October 15, 2004
